Flu-v is under clinical development by Imutex and currently in Phase II for Influenza A Virus, H1N1 Subtype Infections. According to GlobalData, Phase II drugs for Influenza A Virus, H1N1 Subtype Infections have a 69% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Flu-v’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
FLU-v is under development for the prevention of H1N1, influenza A, influenza B. The vaccine candidate is administered subcutaneously in the form of powder for suspension. FLU-v is a T cell vaccine candidate, which is effective against all strains of influenza virus. The vaccine candidate is developed using immune activation technology. It was also under development for pandemic influenza.
For a complete picture of Flu-v’s drug-specific PTSR and LoA scores, buy the report here.